Articles & Resources for Physicians:
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
The American Society of Ketamine Physicians, Psychotherapists, and Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions. The ASKP3 has set standards, and ethical guidelines, for the practice in the theraputic use of ketamine.
KETAMINE TREATMENT FOR DEPRESSION: OPPORTUNITIES FOR CLINICAL INNOVATION AND ETHICAL FORESIGHT
Singh, Ilina et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry, Volume 4 , Issue 5 , 419 - 42.
A review and analysis of ethical considerations in off-label ketamine use for severe, treatment-resistant depression, and a review of the drug's safety profile.
A Time Magazine cover story from 2017, New Hope for Depression, explores one of the latest developments in treatment: ketamine hydrochloride. Read the article on Time.com
A CONSENSUS STATEMENT ON THE USE OF KETAMINE IN THE TREATMENT OF MOOD DISORDERS
Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399–405. doi:10.1001/jamapsychiatry.2017.0080
Studies on Ketamine hydrochloride’s ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment.
EFFICACY OF INTRAVENOUS KETAMINE FOR TREATMENT OF CHRONIC POSTTRAUMATIC STRESS DISORDER: A RANDOMIZED CLINICAL TRIAL
Feder A, Parides MK, Murrough JW, et al. Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress DisorderA Randomized Clinical Trial. JAMA Psychiatry. 2014;71(6):681–688. doi:10.1001/jamapsychiatry.2014.62
Clinical study which tested the efficacy and safety of a single intravenous subanesthetic dose of ketamine for the treatment of PTSD.
Greater reduction of PTSD symptoms following treatment with ketamine was evident in both crossover and first-period analyses, and remained significant after adjusting for baseline and 24-hour depressive symptom severity.
Ketamine was generally well tolerated without clinically significant persistent dissociative symptoms.
This study provides the first evidence for rapid reduction in symptom severity following ketamine infusion in patients with chronic PTSD.